OLE Study to Evaluate Safety / Efficacy of ZD4522

Study identifier:4522IL/0034

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

ZD4522 Long Term Extension Trial

Medical condition

hypercholesterolaemia

Phase

Phase 3

Healthy volunteers

Study drug

Rosuvastatin

Sex

All

Actual Enrollment

3500

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 01 Aug 1999

Primary Completion Date: -

Study Completion Date: 01 Feb 2005

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Rosuvastatin	-

Documents available

CSR-D3560c00034-4522il-0034.pdf
Download
CSR-D3560c00034-4522il-0034.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

[email protected]

Investigators

Principal Investigator

Elinor Miller

AstraZeneca